Cargando…

The survival benefit of increasing the number of active drugs for metastatic colorectal cancer: A multicenter retrospective study

BACKGROUND: The development of chemotherapy and treatment strategies for metastatic colorectal cancer (mCRC) have provided patients with significant survival benefits. Currently, molecular targeting agents and late‐line treatment with regorafenib and trifluridine/tipiracil (FTD/TPI) are available. H...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kawakami, Takeshi, Masuishi, Toshiki, Kawamoto, Yasuyuki, Go, Hirofumi, Kato, Kyoko, Kumanishi, Ryosuke, Sawada, Kentaro, Yuki, Satoshi, Yamamoto, Kouji, Komatsu, Yoshito, Muro, Kei, Fushiki, Kunihiro, Shirasu, Hiromichi, Yamazaki, Kentaro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	RESEARCH ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9160807/ https://www.ncbi.nlm.nih.gov/pubmed/35182029 http://dx.doi.org/10.1002/cam4.4599

Ejemplares similares

Impact of tumour growth rate during preceding treatment on tumour response to regorafenib or trifluridine/tipiracil in refractory metastatic colorectal cancer
por: Masuishi, Toshiki, et al.
Publicado: (2019)

Bevacizumab, Irinotecan, and Biweekly Trifluridine/Tipiracil for Metastatic Colorectal Cancer: MODURATE, a Phase Ib Study
por: Taniguchi, Hiroya, et al.
Publicado: (2023)

Prospective Survey of Financial Toxicity Measured by the Comprehensive Score for Financial Toxicity in Japanese Patients With Cancer
por: Honda, Kazunori, et al.
Publicado: (2019)

Combination of Oxaliplatin and 5-Fluorouracil/Leucovorin for Advanced Esophageal Squamous Cell Carcinoma Refractory or Intolerant to Standard Therapies
por: Mitani, Seiichiro, et al.
Publicado: (2019)

Efficacy and safety of S-1 following gemcitabine with cisplatin for advanced biliary tract cancer
por: Inoue, Hiroto, et al.
Publicado: (2021)

Combination therapy of capecitabine, irinotecan, oxaliplatin, and bevacizumab as a first‐line treatment for metastatic colorectal cancer: Safety lead‐in results from the QUATTRO-II study
por: Kotani, Daisuke, et al.
Publicado: (2021)

Impact of tumor growth rate during preceding treatment on tumor response to nivolumab or irinotecan in advanced gastric cancer
por: Kato, K., et al.
Publicado: (2021)

Randomised phase II trial of trifluridine/tipiracil (FTD/TPI) plus ramucirumab (RAM) versus trifluridine/tipiracil for previously treated patients with advanced gastric or esophagogastric junction adenocarcinoma (RETRIEVE study, WJOG15822G)
por: Takahashi, Naoki, et al.
Publicado: (2023)

Clinical outcomes of patients diagnosed with cancer of unknown primary or malignancy of undefined primary origin who were referred to a regional cancer center
por: Ando, Masashi, et al.
Publicado: (2023)

Efficacy and Safety of Bolus 5-Fluorouracil and L-Leucovorin as Salvage Chemotherapy for Oral Fluoropyrimidine-Resistant Unresectable or Recurrent Gastric Cancer: A Single Center Experience
por: Muranaka, Tetsuhito, et al.
Publicado: (2016)

Biomarker analysis for patients with pancreatic cancer treated with nanoliposomal irinotecan plus 5-fluorouracil/leucovorin
por: Kawakami, Takeshi, et al.
Publicado: (2023)

First experience of a fully decentralized clinical trial: The dawn of a new era in oncology
por: Taniguchi, Hiroya, et al.
Publicado: (2023)

A Phase I Trial of Oxaliplatin, Irinotecan, and S‐1 Combination Therapy (OX‐IRIS) as Chemotherapy for Unresectable Pancreatic Cancer (HGCSG 1403)
por: Kawamoto, Yasuyuki, et al.
Publicado: (2021)

Risk factors for esophageal fistula in thoracic esophageal squamous cell carcinoma invading adjacent organs treated with definitive chemoradiotherapy: a monocentric case-control study
por: Kawakami, Takeshi, et al.
Publicado: (2018)

Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial
por: Nakamura, Yoshiaki, et al.
Publicado: (2021)

Second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer
por: Yamamoto, Shun, et al.
Publicado: (2021)

Protocol of the QUATTRO-II study: a multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as a first-line treatment in patients with metastatic colorectal cancer
por: Miyo, Masaaki, et al.
Publicado: (2020)

A Prospective Trial Evaluating the Safety of a Shortened Infusion of Ramucirumab in Patients with Gastrointestinal Cancer
por: Hashimoto, Naoya, et al.
Publicado: (2018)

Correlation of UGT1A1 Gene Polymorphisms or Prior Irinotecan Treatment and Treatment Outcomes of Nanoliposomal-Irinotecan plus 5-Fluorouracil/Leucovorin for Pancreatic Ductal Adenocarcinoma: A Multicenter, Retrospective Cohort Study (HGCSG2101)
por: Harada, Kazuaki, et al.
Publicado: (2023)

Japanese Society of Medical Oncology Clinical Guidelines: RAS (KRAS/NRAS) mutation testing in colorectal cancer patients11
por: Taniguchi, Hiroya, et al.
Publicado: (2015)

Fluoropyrimidine with or without platinum as first-line chemotherapy in patients with advanced gastric cancer and severe peritoneal metastasis: a multicenter retrospective study
por: Arai, Hiroyuki, et al.
Publicado: (2019)

FMS‐like tyrosine kinase 3 (FLT3) amplification in patients with metastatic colorectal cancer
por: Hasegawa, Hiroko, et al.
Publicado: (2020)

Observational study of first-line chemotherapy including cetuximab in patients with metastatic colorectal cancer: CORAL trial
por: Muro, Kei, et al.
Publicado: (2019)

Phase I study of napabucasin in combination with FOLFIRI + bevacizumab in Japanese patients with metastatic colorectal cancer
por: Taniguchi, Hiroya, et al.
Publicado: (2021)

Renal impairment as a risk factor for trifluridine/tipiracil-induced adverse events in metastatic colorectal cancer patients from the REGOTAS study
por: Shiroyama, Mamiko, et al.
Publicado: (2023)

Japanese Society of Medical Oncology Clinical Guidelines: Molecular Testing for Colorectal Cancer Treatment, Third Edition
por: Yamazaki, Kentaro, et al.
Publicado: (2018)

Convergent evolution in structural elements of proteins investigated using cross profile analysis
por: Tomii, Kentaro, et al.
Publicado: (2012)

Successful Treatment of Cardiac Angiosarcoma Associated with Disseminated Intravascular Coagulation with Nab-Paclitaxel: A Case Report and Review of the Literature
por: Honda, Kazunori, et al.
Publicado: (2017)

The role of biomarker in later-line treatment for metastatic colorectal cancer
por: Kawakami, Takeshi, et al.
Publicado: (2023)

Phase 1 study of efatutazone, a novel oral peroxisome proliferator-activated receptor gamma agonist, in combination with FOLFIRI as second-line therapy in patients with metastatic colorectal cancer
por: Komatsu, Yoshito, et al.
Publicado: (2013)

Feasibility of edoxaban for asymptomatic cancer-associated thrombosis in Japanese patients with gastrointestinal cancer: ExCAVE study
por: Nakamura, Michio, et al.
Publicado: (2022)

Phase I dose‐escalation trial of Sym004, an anti‐EGFR antibody mixture, in Japanese patients with advanced solid tumors
por: Kojima, Takashi, et al.
Publicado: (2018)

Association between the use of antibiotics and efficacy of gemcitabine plus nab-paclitaxel in advanced pancreatic cancer
por: Nakano, Shintaro, et al.
Publicado: (2020)

Anti-epidermal growth factor receptor treatment for patients with NeoRAS wild-type metastatic colorectal cancer: a case report of two cases
por: Harada, Kazuaki, et al.
Publicado: (2023)

CIRCULATE‐Japan: Circulating tumor DNA–guided adaptive platform trials to refine adjuvant therapy for colorectal cancer
por: Taniguchi, Hiroya, et al.
Publicado: (2021)

A prospective survey of comprehensive score for financial toxicity in Japanese cancer patients: report on a pilot study
por: Honda, Kazunori, et al.
Publicado: (2018)

Study protocol of HGCSG1404 SNOW study: a phase I/II trial of combined chemotherapy of S-1, nab-paclitaxel and oxaliplatin administered biweekly to patients with advanced gastric cancer
por: Kawamoto, Yasuyuki, et al.
Publicado: (2017)

Phase II Study of Ramucirumab Plus Irinotecan Combination Therapy as Second-Line Treatment in Patients with Advanced Gastric Cancer: HGCSG1603
por: Kawamoto, Yasuyuki, et al.
Publicado: (2022)

An open-label, crossover study to compare different formulations and evaluate effect of food on pharmacokinetics of pimitespib in patients with advanced solid tumors
por: Komatsu, Yoshito, et al.
Publicado: (2022)

The impact of the Glasgow Prognostic Score on survival in second-line chemotherapy for metastatic colorectal cancer patients with BRAF V600E mutation
por: Mitani, Seiichiro, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_5jrrc0kkbanqe0reqvss6lrb49